SANOFI BCG MATRIX TEMPLATE RESEARCH
Actionable Strategy Starts Here
Sanofi's BCG Matrix snapshot highlights how its flagship vaccine franchises act as Stars in high-growth segments while several mature pharma lines function as Cash Cows funding R&D and pipeline expansion; a few underperforming legacy products sit near the Dogs quadrant and select early-stage biologics remain Question Marks with high upside if trials succeed. Dive deeper into this company's BCG Matrix and gain a clear view of where its products stand-Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.
Stars
Dupixent (Dupilumab) Revenue of €15.7 Billion
Dupixent (dupilumab) remains Sanofi's flagship immunology star, posting €15.7 billion in 2025 revenue and 25.2% growth at constant exchange rates.
Its market share expanded across eight approved indications, led by a high-growth COPD launch now the fastest-growing respiratory segment.
Q4 2025 sales topped €4.2 billion, representing over 35% of Sanofi's total revenue.
Analysts project peak sales of €22 billion by 2030, underpinning its sustained market dominance.
Beyfortus (Nirsevimab) Global Sales of €1.8 Billion
Beyfortus (nirsevimab) reached €1.8 billion in 2025 sales, earning blockbuster status as the first-to-market RSV monoclonal antibody for all infants and growing 9.5% year-over-year despite early supply constraints.
Its presence in over 45 countries and a 105.8% sales surge in Rest of World in Q4 2025 reinforce market dominance and make Beyfortus a key growth engine in Sanofi's vaccines division, capturing the high-demand pediatric immunization segment.
ALTUVIIIO Hemophilia A Sales of €1.2 Billion
ALTUVIIIO Hemophilia A posted €1.2 billion sales in 2025, up 77.6% year-over-year, crossing blockbuster status and disrupting legacy factor VIII treatments.
82% of revenue came from the US, driven by superior efficacy and once-weekly dosing, and ALTUVIIIO has taken double-digit share from older products.
As a Star in Sanofi's BCG matrix, it needs sustained promotional spend but is on a clear path to a dominant, stable market position.
Ayvakit (Avapritinib) Growth of 57% in Specialty Care
Ayvakit (avapritinib), acquired via the 2024 Blueprint Medicines deal, grew 57% in Sanofi's Specialty Care in 2025 and helped drive a 49.4% rise in new pharma launch sales, reaching approximately €420m in 2025 sales for rare-disease launches.
It commands a leading share in systemic mastocytosis, faces limited direct competition, and its fast uptake supports Sanofi's revenue diversification ahead of major patent expiries.
- 2025 Ayvakit growth: 57%
- Contribution to new launches: 49.4% increase
- Approx. 2025 Ayvakit sales: €420m
- Market: niche systemic mastocytosis, high share, limited competition
Sarclisa (Isatuximab) 28.5% Year-over-Year Growth
Sarclisa (isatuximab) is a high-growth leader in multiple myeloma, posting €588 million in 2025 revenue, up 28.5% YoY, driven by new subcutaneous formulation data and label expansions.
It outpaces the blood cancer therapy market, strengthens Sanofi's oncology position, and still consumes R&D and marketing cash but is on track to become a durable cash generator.
- 2025 revenue €588m; +28.5% YoY
- Growth led by subcutaneous formulation and label expansions
- Faster than broader blood-cancer market
- High R&D/marketing spend now; cash generator outlook
Star lineup: Dupixent €15.7bn +25% and high-growth portfolio driving peak potential
Stars: Dupixent €15.7bn (2025, +25.2% CER); Beyfortus €1.8bn (+9.5% YoY); ALTUVIIIO €1.2bn (+77.6%); Ayvakit €420m (+57%); Sarclisa €588m (+28.5%) - high growth, substantial market share, needs continued investment to reach peak potential.
| Product | 2025 Sales | Growth |
|---|---|---|
| Dupixent | €15.7bn | +25.2% CER |
| Beyfortus | €1.8bn | +9.5% YoY |
| ALTUVIIIO | €1.2bn | +77.6% YoY |
| Ayvakit | €420m | +57% YoY |
| Sarclisa | €588m | +28.5% YoY |
What is included in the product
Detailed Word Document
BCG Matrix review of Sanofi: quadrant-by-quadrant strategic guidance on which units to invest, hold, or divest amid key macro/micro trends.
Customizable Excel Spreadsheet
One-page Sanofi BCG Matrix placing each business unit in a quadrant for quick strategic clarity
Cash Cows
Lantus (Insulin Glargine) €1.4 Billion Annual Revenue
Lantus (insulin glargine) generates about €1.4 billion annually and remains the volume leader in the mature basal insulin market despite US generic pressure.
In 2025 Lantus posted windfall quarterly growth of 11.5% amid competitor supply shortages, underscoring resilience and steady cash flow.
Low marketing spend keeps gross margins high-Sanofi can harvest proceeds to fund its high‑growth immunology pipeline.
Influenza Vaccine Franchise €2.5 Billion Revenue
Sanofi's influenza vaccine franchise generated €2.5 billion in 2025 revenue, preserving global market leadership with Q4 performance above internal targets and ~35% global share.
Market growth remains low (~1-2% CAGR) and seasonal, but mature manufacturing yields >30% gross margins and predictable cash flow.
Sanofi redirected cash from this franchise-≈€600-700 million in 2025-to accelerate mRNA and multivalent vaccine R&D and manufacturing scale-up.
Opella Retained Stake (48.2% Ownership)
Following the April 2025 closing of the 50% sale to CD&R, Sanofi's retained 48.2% stake in Opella serves as a cash cow: Opella is valued at €16.0 billion and runs low-growth, high-share brands like Allegra and Doliprane, generating stable dividends; Sanofi received €10.0 billion cash at closing and continues to earn pro rata dividend flows from a mature consumer-health leader.
Toujeo (Insulin Glargine 300 U/mL) Stable Market Share
Toujeo (insulin glargine 300 U/mL) replaces Lantus and holds ~18% global long‑acting insulin market share (2025), with annual sales ~€2.1bn and gross margins ~68%, delivering stable volume and high brand loyalty in a low‑growth, mature segment where formulary access, not new trials, drives competition.
- 2025 sales: €2.1bn
- Global market share: ~18% (long‑acting insulin)
- Gross margin: ~68%
- Role: low incremental costs, cash generator for General Medicines
Lovenox (Enoxaparin Sodium) Legacy Portfolio Sales
Lovenox (enoxaparin sodium) still delivers steady legacy sales for Sanofi, generating roughly €1.1 billion in 2025 global revenue and retaining ~35% share in Europe and strong positions in key emerging markets despite biosimilars.
With low to nil promotional spend, scale manufacturing and brand trust keep gross margins high (~60%), letting Sanofi milk cash to service debt and fund R&D.
- 2025 revenue ~€1.1B
- Europe market share ~35%
- Gross margin ≈60%
- Minimal promo spend
- Funds debt servicing and R&D
Sanofi: €7.1bn core cash engines, high margins, low growth; Opella stake €16bn
Lantus: €1.4bn (2025), Toujeo: €2.1bn, Influenza vaccines: €2.5bn, Lovenox: €1.1bn; high gross margins (60-68%), low growth (1-2% CAGR), predictable cash flows; Opella stake valued €16.0bn (Sanofi received €10.0bn cash at closing, retains 48.2%).
| Product | 2025 sales | Margin | Market share |
|---|---|---|---|
| Lantus | €1.4bn | ~65% | Volume leader |
| Toujeo | €2.1bn | ~68% | ~18% |
| Influenza vaccines | €2.5bn | >30% | ~35% global |
| Lovenox | €1.1bn | ~60% | ~35% Europe |
Delivered as Shown
Sanofi BCG Matrix
The file you're previewing is the final Sanofi BCG Matrix you'll receive after purchase-no watermarks or demo elements, just a fully formatted, analysis-ready report tailored for strategic clarity.
This preview is identical to the downloadable document sent to your inbox: market-backed positioning, clear quadrant mapping, and concise recommendations-no edits required to present or share.
What you see is the actual deliverable unlocked upon purchase, ready for printing, editing, or embedding in investor decks and internal strategy sessions.
Professionally designed for immediate use, the report distills Sanofi's portfolio into actionable insights to support portfolio management, resource allocation, and competitive planning.
Original: $10.00
-65%$10.00
$3.50SANOFI BCG MATRIX TEMPLATE RESEARCH
Actionable Strategy Starts Here
Sanofi's BCG Matrix snapshot highlights how its flagship vaccine franchises act as Stars in high-growth segments while several mature pharma lines function as Cash Cows funding R&D and pipeline expansion; a few underperforming legacy products sit near the Dogs quadrant and select early-stage biologics remain Question Marks with high upside if trials succeed. Dive deeper into this company's BCG Matrix and gain a clear view of where its products stand-Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.
Stars
Dupixent (Dupilumab) Revenue of €15.7 Billion
Dupixent (dupilumab) remains Sanofi's flagship immunology star, posting €15.7 billion in 2025 revenue and 25.2% growth at constant exchange rates.
Its market share expanded across eight approved indications, led by a high-growth COPD launch now the fastest-growing respiratory segment.
Q4 2025 sales topped €4.2 billion, representing over 35% of Sanofi's total revenue.
Analysts project peak sales of €22 billion by 2030, underpinning its sustained market dominance.
Beyfortus (Nirsevimab) Global Sales of €1.8 Billion
Beyfortus (nirsevimab) reached €1.8 billion in 2025 sales, earning blockbuster status as the first-to-market RSV monoclonal antibody for all infants and growing 9.5% year-over-year despite early supply constraints.
Its presence in over 45 countries and a 105.8% sales surge in Rest of World in Q4 2025 reinforce market dominance and make Beyfortus a key growth engine in Sanofi's vaccines division, capturing the high-demand pediatric immunization segment.
ALTUVIIIO Hemophilia A Sales of €1.2 Billion
ALTUVIIIO Hemophilia A posted €1.2 billion sales in 2025, up 77.6% year-over-year, crossing blockbuster status and disrupting legacy factor VIII treatments.
82% of revenue came from the US, driven by superior efficacy and once-weekly dosing, and ALTUVIIIO has taken double-digit share from older products.
As a Star in Sanofi's BCG matrix, it needs sustained promotional spend but is on a clear path to a dominant, stable market position.
Ayvakit (Avapritinib) Growth of 57% in Specialty Care
Ayvakit (avapritinib), acquired via the 2024 Blueprint Medicines deal, grew 57% in Sanofi's Specialty Care in 2025 and helped drive a 49.4% rise in new pharma launch sales, reaching approximately €420m in 2025 sales for rare-disease launches.
It commands a leading share in systemic mastocytosis, faces limited direct competition, and its fast uptake supports Sanofi's revenue diversification ahead of major patent expiries.
- 2025 Ayvakit growth: 57%
- Contribution to new launches: 49.4% increase
- Approx. 2025 Ayvakit sales: €420m
- Market: niche systemic mastocytosis, high share, limited competition
Sarclisa (Isatuximab) 28.5% Year-over-Year Growth
Sarclisa (isatuximab) is a high-growth leader in multiple myeloma, posting €588 million in 2025 revenue, up 28.5% YoY, driven by new subcutaneous formulation data and label expansions.
It outpaces the blood cancer therapy market, strengthens Sanofi's oncology position, and still consumes R&D and marketing cash but is on track to become a durable cash generator.
- 2025 revenue €588m; +28.5% YoY
- Growth led by subcutaneous formulation and label expansions
- Faster than broader blood-cancer market
- High R&D/marketing spend now; cash generator outlook
Star lineup: Dupixent €15.7bn +25% and high-growth portfolio driving peak potential
Stars: Dupixent €15.7bn (2025, +25.2% CER); Beyfortus €1.8bn (+9.5% YoY); ALTUVIIIO €1.2bn (+77.6%); Ayvakit €420m (+57%); Sarclisa €588m (+28.5%) - high growth, substantial market share, needs continued investment to reach peak potential.
| Product | 2025 Sales | Growth |
|---|---|---|
| Dupixent | €15.7bn | +25.2% CER |
| Beyfortus | €1.8bn | +9.5% YoY |
| ALTUVIIIO | €1.2bn | +77.6% YoY |
| Ayvakit | €420m | +57% YoY |
| Sarclisa | €588m | +28.5% YoY |
What is included in the product
Detailed Word Document
BCG Matrix review of Sanofi: quadrant-by-quadrant strategic guidance on which units to invest, hold, or divest amid key macro/micro trends.
Customizable Excel Spreadsheet
One-page Sanofi BCG Matrix placing each business unit in a quadrant for quick strategic clarity
Cash Cows
Lantus (Insulin Glargine) €1.4 Billion Annual Revenue
Lantus (insulin glargine) generates about €1.4 billion annually and remains the volume leader in the mature basal insulin market despite US generic pressure.
In 2025 Lantus posted windfall quarterly growth of 11.5% amid competitor supply shortages, underscoring resilience and steady cash flow.
Low marketing spend keeps gross margins high-Sanofi can harvest proceeds to fund its high‑growth immunology pipeline.
Influenza Vaccine Franchise €2.5 Billion Revenue
Sanofi's influenza vaccine franchise generated €2.5 billion in 2025 revenue, preserving global market leadership with Q4 performance above internal targets and ~35% global share.
Market growth remains low (~1-2% CAGR) and seasonal, but mature manufacturing yields >30% gross margins and predictable cash flow.
Sanofi redirected cash from this franchise-≈€600-700 million in 2025-to accelerate mRNA and multivalent vaccine R&D and manufacturing scale-up.
Opella Retained Stake (48.2% Ownership)
Following the April 2025 closing of the 50% sale to CD&R, Sanofi's retained 48.2% stake in Opella serves as a cash cow: Opella is valued at €16.0 billion and runs low-growth, high-share brands like Allegra and Doliprane, generating stable dividends; Sanofi received €10.0 billion cash at closing and continues to earn pro rata dividend flows from a mature consumer-health leader.
Toujeo (Insulin Glargine 300 U/mL) Stable Market Share
Toujeo (insulin glargine 300 U/mL) replaces Lantus and holds ~18% global long‑acting insulin market share (2025), with annual sales ~€2.1bn and gross margins ~68%, delivering stable volume and high brand loyalty in a low‑growth, mature segment where formulary access, not new trials, drives competition.
- 2025 sales: €2.1bn
- Global market share: ~18% (long‑acting insulin)
- Gross margin: ~68%
- Role: low incremental costs, cash generator for General Medicines
Lovenox (Enoxaparin Sodium) Legacy Portfolio Sales
Lovenox (enoxaparin sodium) still delivers steady legacy sales for Sanofi, generating roughly €1.1 billion in 2025 global revenue and retaining ~35% share in Europe and strong positions in key emerging markets despite biosimilars.
With low to nil promotional spend, scale manufacturing and brand trust keep gross margins high (~60%), letting Sanofi milk cash to service debt and fund R&D.
- 2025 revenue ~€1.1B
- Europe market share ~35%
- Gross margin ≈60%
- Minimal promo spend
- Funds debt servicing and R&D
Sanofi: €7.1bn core cash engines, high margins, low growth; Opella stake €16bn
Lantus: €1.4bn (2025), Toujeo: €2.1bn, Influenza vaccines: €2.5bn, Lovenox: €1.1bn; high gross margins (60-68%), low growth (1-2% CAGR), predictable cash flows; Opella stake valued €16.0bn (Sanofi received €10.0bn cash at closing, retains 48.2%).
| Product | 2025 sales | Margin | Market share |
|---|---|---|---|
| Lantus | €1.4bn | ~65% | Volume leader |
| Toujeo | €2.1bn | ~68% | ~18% |
| Influenza vaccines | €2.5bn | >30% | ~35% global |
| Lovenox | €1.1bn | ~60% | ~35% Europe |
Delivered as Shown
Sanofi BCG Matrix
The file you're previewing is the final Sanofi BCG Matrix you'll receive after purchase-no watermarks or demo elements, just a fully formatted, analysis-ready report tailored for strategic clarity.
This preview is identical to the downloadable document sent to your inbox: market-backed positioning, clear quadrant mapping, and concise recommendations-no edits required to present or share.
What you see is the actual deliverable unlocked upon purchase, ready for printing, editing, or embedding in investor decks and internal strategy sessions.
Professionally designed for immediate use, the report distills Sanofi's portfolio into actionable insights to support portfolio management, resource allocation, and competitive planning.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Actionable Strategy Starts Here
Sanofi's BCG Matrix snapshot highlights how its flagship vaccine franchises act as Stars in high-growth segments while several mature pharma lines function as Cash Cows funding R&D and pipeline expansion; a few underperforming legacy products sit near the Dogs quadrant and select early-stage biologics remain Question Marks with high upside if trials succeed. Dive deeper into this company's BCG Matrix and gain a clear view of where its products stand-Stars, Cash Cows, Dogs, or Question Marks. Purchase the full version for a complete breakdown and strategic insights you can act on.
Stars
Dupixent (Dupilumab) Revenue of €15.7 Billion
Dupixent (dupilumab) remains Sanofi's flagship immunology star, posting €15.7 billion in 2025 revenue and 25.2% growth at constant exchange rates.
Its market share expanded across eight approved indications, led by a high-growth COPD launch now the fastest-growing respiratory segment.
Q4 2025 sales topped €4.2 billion, representing over 35% of Sanofi's total revenue.
Analysts project peak sales of €22 billion by 2030, underpinning its sustained market dominance.
Beyfortus (Nirsevimab) Global Sales of €1.8 Billion
Beyfortus (nirsevimab) reached €1.8 billion in 2025 sales, earning blockbuster status as the first-to-market RSV monoclonal antibody for all infants and growing 9.5% year-over-year despite early supply constraints.
Its presence in over 45 countries and a 105.8% sales surge in Rest of World in Q4 2025 reinforce market dominance and make Beyfortus a key growth engine in Sanofi's vaccines division, capturing the high-demand pediatric immunization segment.
ALTUVIIIO Hemophilia A Sales of €1.2 Billion
ALTUVIIIO Hemophilia A posted €1.2 billion sales in 2025, up 77.6% year-over-year, crossing blockbuster status and disrupting legacy factor VIII treatments.
82% of revenue came from the US, driven by superior efficacy and once-weekly dosing, and ALTUVIIIO has taken double-digit share from older products.
As a Star in Sanofi's BCG matrix, it needs sustained promotional spend but is on a clear path to a dominant, stable market position.
Ayvakit (Avapritinib) Growth of 57% in Specialty Care
Ayvakit (avapritinib), acquired via the 2024 Blueprint Medicines deal, grew 57% in Sanofi's Specialty Care in 2025 and helped drive a 49.4% rise in new pharma launch sales, reaching approximately €420m in 2025 sales for rare-disease launches.
It commands a leading share in systemic mastocytosis, faces limited direct competition, and its fast uptake supports Sanofi's revenue diversification ahead of major patent expiries.
- 2025 Ayvakit growth: 57%
- Contribution to new launches: 49.4% increase
- Approx. 2025 Ayvakit sales: €420m
- Market: niche systemic mastocytosis, high share, limited competition
Sarclisa (Isatuximab) 28.5% Year-over-Year Growth
Sarclisa (isatuximab) is a high-growth leader in multiple myeloma, posting €588 million in 2025 revenue, up 28.5% YoY, driven by new subcutaneous formulation data and label expansions.
It outpaces the blood cancer therapy market, strengthens Sanofi's oncology position, and still consumes R&D and marketing cash but is on track to become a durable cash generator.
- 2025 revenue €588m; +28.5% YoY
- Growth led by subcutaneous formulation and label expansions
- Faster than broader blood-cancer market
- High R&D/marketing spend now; cash generator outlook
Star lineup: Dupixent €15.7bn +25% and high-growth portfolio driving peak potential
Stars: Dupixent €15.7bn (2025, +25.2% CER); Beyfortus €1.8bn (+9.5% YoY); ALTUVIIIO €1.2bn (+77.6%); Ayvakit €420m (+57%); Sarclisa €588m (+28.5%) - high growth, substantial market share, needs continued investment to reach peak potential.
| Product | 2025 Sales | Growth |
|---|---|---|
| Dupixent | €15.7bn | +25.2% CER |
| Beyfortus | €1.8bn | +9.5% YoY |
| ALTUVIIIO | €1.2bn | +77.6% YoY |
| Ayvakit | €420m | +57% YoY |
| Sarclisa | €588m | +28.5% YoY |
What is included in the product
Detailed Word Document
BCG Matrix review of Sanofi: quadrant-by-quadrant strategic guidance on which units to invest, hold, or divest amid key macro/micro trends.
Customizable Excel Spreadsheet
One-page Sanofi BCG Matrix placing each business unit in a quadrant for quick strategic clarity
Cash Cows
Lantus (Insulin Glargine) €1.4 Billion Annual Revenue
Lantus (insulin glargine) generates about €1.4 billion annually and remains the volume leader in the mature basal insulin market despite US generic pressure.
In 2025 Lantus posted windfall quarterly growth of 11.5% amid competitor supply shortages, underscoring resilience and steady cash flow.
Low marketing spend keeps gross margins high-Sanofi can harvest proceeds to fund its high‑growth immunology pipeline.
Influenza Vaccine Franchise €2.5 Billion Revenue
Sanofi's influenza vaccine franchise generated €2.5 billion in 2025 revenue, preserving global market leadership with Q4 performance above internal targets and ~35% global share.
Market growth remains low (~1-2% CAGR) and seasonal, but mature manufacturing yields >30% gross margins and predictable cash flow.
Sanofi redirected cash from this franchise-≈€600-700 million in 2025-to accelerate mRNA and multivalent vaccine R&D and manufacturing scale-up.
Opella Retained Stake (48.2% Ownership)
Following the April 2025 closing of the 50% sale to CD&R, Sanofi's retained 48.2% stake in Opella serves as a cash cow: Opella is valued at €16.0 billion and runs low-growth, high-share brands like Allegra and Doliprane, generating stable dividends; Sanofi received €10.0 billion cash at closing and continues to earn pro rata dividend flows from a mature consumer-health leader.
Toujeo (Insulin Glargine 300 U/mL) Stable Market Share
Toujeo (insulin glargine 300 U/mL) replaces Lantus and holds ~18% global long‑acting insulin market share (2025), with annual sales ~€2.1bn and gross margins ~68%, delivering stable volume and high brand loyalty in a low‑growth, mature segment where formulary access, not new trials, drives competition.
- 2025 sales: €2.1bn
- Global market share: ~18% (long‑acting insulin)
- Gross margin: ~68%
- Role: low incremental costs, cash generator for General Medicines
Lovenox (Enoxaparin Sodium) Legacy Portfolio Sales
Lovenox (enoxaparin sodium) still delivers steady legacy sales for Sanofi, generating roughly €1.1 billion in 2025 global revenue and retaining ~35% share in Europe and strong positions in key emerging markets despite biosimilars.
With low to nil promotional spend, scale manufacturing and brand trust keep gross margins high (~60%), letting Sanofi milk cash to service debt and fund R&D.
- 2025 revenue ~€1.1B
- Europe market share ~35%
- Gross margin ≈60%
- Minimal promo spend
- Funds debt servicing and R&D
Sanofi: €7.1bn core cash engines, high margins, low growth; Opella stake €16bn
Lantus: €1.4bn (2025), Toujeo: €2.1bn, Influenza vaccines: €2.5bn, Lovenox: €1.1bn; high gross margins (60-68%), low growth (1-2% CAGR), predictable cash flows; Opella stake valued €16.0bn (Sanofi received €10.0bn cash at closing, retains 48.2%).
| Product | 2025 sales | Margin | Market share |
|---|---|---|---|
| Lantus | €1.4bn | ~65% | Volume leader |
| Toujeo | €2.1bn | ~68% | ~18% |
| Influenza vaccines | €2.5bn | >30% | ~35% global |
| Lovenox | €1.1bn | ~60% | ~35% Europe |
Delivered as Shown
Sanofi BCG Matrix
The file you're previewing is the final Sanofi BCG Matrix you'll receive after purchase-no watermarks or demo elements, just a fully formatted, analysis-ready report tailored for strategic clarity.
This preview is identical to the downloadable document sent to your inbox: market-backed positioning, clear quadrant mapping, and concise recommendations-no edits required to present or share.
What you see is the actual deliverable unlocked upon purchase, ready for printing, editing, or embedding in investor decks and internal strategy sessions.
Professionally designed for immediate use, the report distills Sanofi's portfolio into actionable insights to support portfolio management, resource allocation, and competitive planning.
